Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones

被引：10

作者：

Reinert, RR

Al-Lahham, A

Lütticken, R

Boos, M

Schmitz, FJ

机构：

[1] Univ Aachen, Inst Med Microbiol, Natl Reference Ctr Streptococci, D-52074 Aachen, Germany

[2] Univ Hosp Dusseldorf, Inst Med Microbiol & Virol, Dusseldorf, Germany

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2002年 / 49卷 / 06期

关键词：

D O I：

10.1093/jac/dkf036

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Fourteen pneumococcal strains isolated in three nationwide studies were characterized for amino acid changes in the enzymes GyrA, GyrB, ParC and ParE, and for the in vitro activity of eight fluoroquinolones and the new non-fluorinated quinolone BMS 284756. Gemifloxacin and BMS 284756 exhibited the best in vitro activity against all 14 isolates tested. In nine of the 14 isolates mainly classical alterations in ParC (D83N/Y, S79Y/F), as well as rarer alterations such as S80P and D78N, contributed to the decreased susceptibility to fluoroquinolones. In two of the 14 isolates the classical alteration in GyrA (S81F) was found. In only one isolate did alterations in ParC and GyrA exist in parallel.

引用

收藏

页码：1015 / 1018

页数：4

相关论文

共 10 条

[1] Pneumococcal resistance to beta-lactam antibiotics: A global geographic overview [J].

Baquero, F .

MICROBIAL DRUG RESISTANCE, 1995, 1 (02) :115-120

[2] In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus [J].

Boos, M ;

Mayer, S ;

Fischer, A ;

Köhrer, K ;

Scheuring, S ;

Heisig, P ;

Verhoef, J ;

Fluit, AC ;

Schmitz, FJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :938-942

[3] Antipneumococcal activities of gemifloxacin compared to those of nine other agents [J].

Davies, TA ;

Kelly, LM ;

Pankuch, GA ;

Credito, KL ;

Jacobs, MR ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :304-310

[4] High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA [J].

Janoir, C ;

Zeller, V ;

Kitzis, MD ;

Moreau, NJ ;

Gutmann, L .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2760-2764

[5] ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype [J].

Munoz, R ;

DelaCampa, AG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2252-2257

[6]

National Committee for Clinical Laboratory Standards, 2000, M7A5 NCCLS

[7] Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae [J].

Pan, XS ;

Ambler, J ;

Mehtar, S ;

Fisher, LM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2321-2326

[8] Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany [J].

Reinert, RR ;

Al-Lahham, A ;

Lemperle, M ;

Tenholte, C ;

Briefs, C ;

Haupts, S ;

Gerards, HH ;

Lütticken, R .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (01) :61-68

[9] Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999.: Results of a National Surveillance Study [J].

Reinert, RR ;

Simic, S ;

Al-Lahham, A ;

Reinert, S ;

Lemperle, M ;

Lütticken, R .

JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (03) :1187-1189

[10] Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC [J].

Schmitz, FJ ;

Jones, ME ;

Hofmann, B ;

Hansen, B ;

Scheuring, S ;

Lückefahr, M ;

Fluit, A ;

Verhoef, J ;

Hadding, U ;

Heinz, HP ;

Köhrer, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) :1249-1252